PetCaseFinder

Peer-reviewed veterinary case report

Limb-sparing surgery with 3D-printed implants for dogs with radial

By Séguin, Bernard et al.·Published in Veterinary and comparative oncology·2020·Department of Clinical Sciences·View original on PubMed

PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →

Original publication title: Limb-sparing in dogs using patient-specific, three-dimensional-printed endoprosthesis for distal radial osteosarcoma: A pilot study.

Species:
dog
OsteosarcomaMovement & jointsDogs

Plain-English summary

A 7-year-old mixed-breed dog was diagnosed with distal radial osteosarcoma (a type of bone cancer) and underwent a limb-sparing surgery using a custom-made, 3D-printed implant. The surgery was planned using CT scans, and the dog received intra-arterial chemotherapy with carboplatin to help control tumor growth while waiting for the implant. Although all dogs experienced some complications, the fit of the implant was generally good, and most dogs lived for over a year after the procedure, with one dog surviving for nearly 18 months. This approach shows promise for treating bone cancer in dogs while preserving their limbs.

People also search for: dog osteosarcoma treatment · 3D-printed implant for dog cancer · intra-arterial chemotherapy for dogs

Abstract

Limb-sparing for distal radial osteosarcoma has a high rate of complications. Using personalized three-dimensional (3D)-printed implants might improve outcome. The goals of this study were to optimize use of patient-specific, 3D-printed endoprostheses for limb-sparing in dogs in the clinical environment and to report the outcome. This was a pilot study where five client-owned dogs were enrolled. Computed tomography (CT) of the thoracic limbs was performed, which was used to create patient-specific endoprostheses and cutting guides, and repeated on the day of surgery. Intra-arterial (IA) carboplatin was introduced in the clinical management. Limb-sparing was performed. Outcome measures were time required to produce the endoprosthesis and cutting guide, fit between cutting guide and endoprosthesis with host bones, gait analysis, size of the tumour, percent tumour necrosis, complications, disease-free interval (DFI) and survival time (ST). Four dogs received IA carboplatin. Excessive tumour growth between planning CT and surgery did not occur in any dog. The interval between the CT and surgery ranged from 14 to 70 days. Fit between the cutting-guide and endoprosthesis with the host bones was good to excellent. At least one complication occurred in all dogs. Two dogs were euthanized with STs of 192 and 531 days. The other dogs were alive with a follow up of 534 to 575 days. IA chemotherapy is a promising strategy to minimize the risk of excessive tumour growth while waiting for the endoprosthesis and cutting-guide to be made. The design of the cutting-guide was critical for best fit of the endoprosthesis with host bones.

Find similar cases for your pet

PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.

Search related cases →

Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/31209977/